INTRODUCTION
PLA 2 are ubiquitous enzymes that hydrolyse the sn-2-acyl bond of cell membrane phospholipids and lipoproteins and yield free fatty acids and lysophospholipids, precursors of various proinflammatory lipid mediators, including leukotrienes, prostaglandins and platelet-activating factor. 1 Mammalian PLA 2 are subdivided into two major families: low molecular mass secretory enzymes (sPLA 2 ) consisting of four types (I, II, V, and X), and high molecular mass cytosolic PLA 2 existing as two types (IV or cPLA 2 and VI or iPLA 2 ). 2, 3 sPLA 2 -IIA is highly expressed in several types of mammalian cells and tissues, and this enzyme acts as a critical modulator of cytokine-mediated synovial inflammatory diseases, may provide the substrate for both cyclooxygenase (COX) and 5-lipoxygenase (5-LO) product formation in mouse bone marrow-derived mast cells. 8 Elevated levels of sPLA 2 have been reported in various body fluids from humans with several inflammatory conditions, including systemic inflammatory response syndrome encompassing sepsis and multiple organ trauma, 9 acute pancreatitis 10 and inflammatory bowel disease. 11, 12 The role of sPLA 2 in various inflammatory conditions will be determined only when potent, specific inhibitors of sPLA 2 are developed and evaluated in the clinic. As a step toward achieving this goal, we performed Quantitative Structure-Activity Relationship (QSAR) analysis to study the human non-pancreatic sPLA 2 inhibitory activity of a series of indole analogues. The present study was aimed at rationalizing the substituent variations of these analogues to provide insight for the future endeavours.
QSAR is a type of analysis where some measures of chemical properties are correlated with biological activity to derive a mathematical illustration of the underlying Structure Activity Relationship (SAR). 13 QSAR studies are unquestionably of great importance in modern chemistry and biochemistry. To get an insight into the SAR we need molecular descriptors that can effectively characterize molecular size, molecular branching or the variations in molecular shapes, and can influence the structure and its activities. 14 Design and development of new drugs is simplified and made more cost-effective because of the advances in the concepts of QSAR studies. A methodology of QSAR studies is one of the approaches to the rational drug design. 15 The introduction of Hansch model, in early 1960, enabled chemists to describe the structure activity relationships in quantitative terms and check those using statistical methods. 16 QSAR are statistically derived models that can be used to predict the biological activity of untested compounds from their molecular structures. 17, 18 This concept helps to understand the role of physicochemical descriptors of compounds in determining the biological activity and in estimating the characteristics of the new and potent compounds, without the chemical synthesis of the compounds. 16 Docking various ligands to the protein of interest followed by scoring to determine the affinity of binding and to reveal the strength of interaction has also become increasingly important in the context of drug discovery. 19 Thus, the objective of the present work was to develop various QSAR models by Multiple Linear Regression (MLR) methods and to use the best QSAR model for the prediction of sPLA 2 inhibitory activity of newly designed compounds by using Scigress explorer software suite. We also performed the molecular docking of the newly designed compounds against sPLA 2 
METHODS

Data set for 3D QSAR
The first step in developing QSAR equations was to compile a list of compounds for which the experimentally determined inhibitory activity was known. The data set was divided into training set for model generation, and a test set for model validation, containing 20 and 12 compounds respectively. The human non-pancreatic sPLA 2 inhibitory activity data (IC 50 ) and chemical structures of indole analogues for training set were retrieved from PubChem database. 21, 22 The biological activity (IC 50 ) of the molecules were converted to their corresponding pIC 50 values, 23 and used as dependent variables in the QSAR calculations (Table 1) . 
Chemical structure construction and optimization
The molecules were drawn using chemical drawing software "ACD/ChemSketch", 24 and 3D optimization of molecules was done by "ACD/3D viewer". 25 Structures of the training set and test set compounds are illustrated in Figure 1 and 2 respectively. The molecules were first optimized to their lowest energy state using Merck Molecular Force Field-3 (MMFF3) method, 26 using Scigress explorer software suite. To avoid the local stable conformations of the compounds, geometry optimization was run many times with different starting points of each molecule, and conformation with the lowest energy was considered for the calculation of the molecule descriptors. 
Calculation of physicochemical descriptors
The structure of a molecule is expressed quantitatively in terms of its physicochemical descriptors, which are lipophilic, electronic and steric in nature. The aligned molecules were selected for calculation of the descriptors after inserting the biological activity as a dependent variable and the descriptors generated were selected as independent variables. List of physicochemical descriptors used in this study are summarised in Table 2 . 
Development and validation of QSAR models
The QSAR studies were carried out to correlate physicochemical descriptors of 20 derivatives from the training set with their sPLA 2 inhibitory activity. The physicochemical descriptors were taken as the independent variables and the human non-pancreatic sPLA 2 inhibitory activity was taken as the dependent variable. Various QSAR models were developed by correlating more than one (stepwise MLR analysis implemented in Scigress explorer's "Project Leader" program) physicochemical descriptors at a time, with sPLA 2 inhibitory activity of the compounds. Validation parameter, predictive r 2 (r 2 pred) was calculated for evaluating the predictive capacity of the models. The models were then cross-validated by the "leave one out" scheme, 27 where a model was built with n-1 compounds and the n th compound was predicted. Each compound was left out of the model derivation and predicted in turn. An indication of the performance of the model was obtained from the cross-validated r 2 CV (or predictive q 2 ) coefficient which is defined as:
Where, SD is the sum of squares deviation for each activity from the mean. PRESS (or predictive sum-ofsquares) is the sum of the squared difference between the actual and that of the predicted values when the compound is omitted from the fitting process. Crossvalidation coefficient q 2 is considered as an indicator of the predictive performance and stability of a model. For a reliable model, the square of cross-validation coefficient q 2 should be ≥ 0.5. 28 The sPLA 2 inhibitory activity of 20 compounds in the training set and 12 compounds in the test set was predicted using the best QSAR model (Equation 1). For further validation of the accuracy of the predicted values by the best QSAR model, the experimental human non-pancreatic sPLA 2 inhibitory activity of the 20 training set of compounds was correlated with their predicted sPLA 2 inhibitory activity.
Graphical analysis
Graphical analysis was performed using Scigress explorer"s plotting facilities to display molecules that were outliers in the database. Through scatter plot there was evaluation of regression in the graph. By plotting the actual activities along X-axis versus the predicted activities along Y-axis, the predicted ability of the model was assessed. From the regression line it was easy to predict the number of molecules lie on and away from regression line.
Receptor X-ray structure
The 3D coordinates of the crystal structure of human non-pancreatic sPLA 2 in complex with 3-1-enzyl-3-carbamoylmethyl-2-methyl-1 -indol-5-yloxy -propyl--phosphonic acid N PD code 1D 4 extracted from the protein data bank www.rcsb.org/ ) was selected as the receptor model for docking experiments.
Docking analysis
We used the template docking available in Molegro Virtual Docker software and evaluated MolDock, Rerank and protein-ligand interaction scores from MolDock and MolDock [GRID] options. Template docking is based on extracting the chemical properties like the pharmacophore elements of a ligand bound in the active site and using that information for docking structurally similar analogues. We used the default settings, including a grid resolution of 0.30 Å for grid generation and a 15 Å radius from the template as the binding site. We used the MolDock optimizer as a search algorithm, and the number of runs was set to 10. A population size of 50, maximum iteration of 2000, scaling factor of 0.50, crossover rate of 0.90 and a variation based termination scheme for parameter settings were used. The maximum number of poses was set to a default value of 5. Table 2 were calculated for the training set of molecules using the Scigress explorer's "Project Leader" program. uman non-pancreatic sPLA 2 inhibitory activity (experimental activity) of all the training compounds was added manually in the data set and was correlated with the different physicochemical descriptors by stepwise MLR analysis and QSAR models were generated. The best model (equation 1) was validated using leave-one-out method and found to be statistically significant, with coefficient of determination (r 2 pred) of 0.788 and crossvalidated r 2 CV (or predictive q 2 ) coefficient of 0.692. (Table 3) .
RESULTS
Physicochemical descriptors listed in
In order to validate our results we correlated the predicted activities of 20 molecules of the training set using the model expressed by equation 1 and compared with the experimental values. Predicted and the experimental activities were very close to each other evidenced by low values of residual activity (difference between experimentally observed activity and QSAR predicted activity) ( Table 4 ). The graph between predicted and experimental activity of training set compounds by using model 1 is illustrated in Figure 3 . Through this scatter plot, the compounds aligned on and around the regression line showed good correlation level between the predicted and experimental activity and compounds which were deviated from the regression line showed low correlation level between the predicted and experimental activity of training set of compounds. Variations in residual activity of training set of compounds are illustrated in Figure 4 . Before the docking experiments, the protocol was validated. 1DB4 (PDB ID) bound ligand [3-(1-Benzyl-3-carbamoylmethyl-2-methyl-1H-indol-5-yloxy)-propyl-]-phosphonic acid (8IN) was docked into the binding pocket of sPLA 2 protein to obtain the docked pose and the RMSD (Root Mean Square Deviation) of all atoms between these two conformations indicating that the parameters for docking simulation were good in reproducing the X-ray crystal structure. Therefore, indole analogues (12 test set of molecules) were docked into the binding pocket of sPLA 2 protein. 1DB4 co-crystallized ligand resulted in MolDock score of -177.358 kcal/mol. Therefore, any molecule from the dataset which shows a score lower than -177.358 kcal/mol would be regarded as ligand with higher binding affinity and would act as inhibitor against sPLA 2 protein. Our approach identified three compounds from the test set of molecules with better energy scores than the 1DB4 bound co-crystallized ligand. The docked energies (Moldock score) and H-bond interaction data of the three best compounds from the 12 test set of molecules are given in Table 5 . 
DISCUSSION
Finding novel compounds at starting points for lead optimization is a major challenge in drug discovery. The number of methods and softwares which use the QSAR and docking approaches are increasing at a rapid pace. It has been clearly demonstrated that the approach utilized in this study was successful in finding novel sPLA 2 inhibitors from the data set developed by computational methods. The model generated from various physicochemical descriptors corresponds to the essential structural features of indole analogues and found to have significant correlation [coefficient of determination (r 2 ) of 0.788] with sPLA 2 inhibiting activity. Substituted indole analogues designed by using computational approaches also showed good interactions with sPLA 2 protein.
Compound (12) , in particular, showed high binding affinity with MolDock score of -183.162 kcal/mol against 1DB4 (PDB ID) in docking analysis and predicted pIC50 value of 7.454 in QSAR analysis. The ligand was docked deeply within the binding pocket region forming hydrogen bond interactions with Asp48, Cys44, His27, Gly29 and Gly31. This study shall help in rational drug design and synthesis of new selective sPLA 2 inhibitors with predetermined affinity and activity and provides valuable information for the understanding of interactions between sPLA 2 and the novel compounds and might pave the way towards discovery of novel sPLA 2 inhibitors. The physicochemical descriptors used in QSAR analysis in this study were important in further lead optimization of the substituted indole derivatives.
